On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia

Expert Opinion on Pharmacotherapy
Laura S Samples, Solomon Graf

Abstract

Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade, refinement of CLL risk stratification tools and growth of the arsenal of effective therapeutics have profoundly improved outcomes. These advances have concurrently increased the complexity of managing the early phases of treatment. This review describes the factors considered in the determination of first-line treatment of CLL. Areas of emphasis include assessment of patient fitness, disease classification and risk stratification, and the mechanisms, efficacy, and toxicities associated with available pharmacotherapeutics. Multiple different treatments may be appropriate for a specific clinical scenario, and selection among them requires discussion of relative risks and benefits. Advances in frontline CLL treatment will continue to shift the treatment paradigm toward prioritizing quality of life alongside survival, limiting treatment and toxicity, and the development of biologically rational synergistic drug combinations and s...Continue Reading

References

Feb 13, 2001·British Journal of Haematology·T Hamblin
Feb 7, 2009·Leukemia & Lymphoma·Barbara EichhorstMichael Hallek
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang U KnaufMarco Montillo
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thorsten ZenzStephan Stilgenbauer
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans WildiersArti Hurria
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Dec 8, 2015·The New England Journal of Medicine·John C ByrdRichard R Furman
Mar 26, 2016·Blood·Timothy P Hughes, David M Ross
Apr 30, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Massimo GentileFortunato Morabito
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Qiushi ChenJagpreet Chhatwal
Dec 3, 2016·Haematologica·Paolo Ghia, Antonio Cuneo
Dec 17, 2016·Nature Communications·Zhikun ZhaoMichael Dean
Jan 13, 2017·Cancer Treatment Reviews·Tadeusz RobakAlessandra Tedeschi
Jan 20, 2017·Nature Reviews. Disease Primers·Thomas J KippsKanti Rai
Feb 10, 2017·Drug Design, Development and Therapy·Othman Al-SawafValentin Goede
Mar 23, 2017·Blood·Kirsten FischerMichael Hallek
May 11, 2017·Journal of Geriatric Oncology·Rachael B Rowswell-Turner, Paul M Barr
Jun 2, 2017·International Journal of Cancer. Journal International Du Cancer·Madar TalibovEero Pukkala
Jul 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cameron J TurtleDavid G Maloney

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.